Pulse Biosciences (NASDAQ:PLSE) was downgraded by equities researchers at BidaskClub from a “hold” rating to a “sell” rating in a note issued to investors on Saturday.
Shares of NASDAQ:PLSE opened at $16.40 on Friday. Pulse Biosciences has a one year low of $9.81 and a one year high of $39.50.
Pulse Biosciences (NASDAQ:PLSE) last announced its quarterly earnings data on Tuesday, May 8th. The company reported ($0.51) EPS for the quarter.
Several large investors have recently made changes to their positions in the company. Citadel Advisors LLC acquired a new stake in shares of Pulse Biosciences during the 4th quarter valued at $7,975,000. Deutsche Bank AG lifted its holdings in shares of Pulse Biosciences by 141.3% in the fourth quarter. Deutsche Bank AG now owns 20,305 shares of the company’s stock valued at $478,000 after purchasing an additional 11,890 shares in the last quarter. Millennium Management LLC purchased a new stake in shares of Pulse Biosciences in the fourth quarter valued at $290,000. Alliancebernstein L.P. purchased a new stake in shares of Pulse Biosciences in the fourth quarter valued at $248,000. Finally, Brown Advisory Inc. purchased a new stake in shares of Pulse Biosciences in the fourth quarter valued at $248,000. Institutional investors own 8.96% of the company’s stock.
Pulse Biosciences Company Profile
Pulse Biosciences, Inc, a clinical-stage medical technology company, develops therapeutic tissue treatment platform based on its proprietary nano-pulse stimulation (NPS) technology. Its NPS is a non-thermal, precise, and focal drug-free tissue treatment technology that initiates cell death within treated tissue used in oncology, dermatology/aesthetics, minimally invasive, and veterinary applications.
Receive News & Ratings for Pulse Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pulse Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.